Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy
Open Access
Abstract
Fabry disease (FD) is a lysosomal disorder caused by α-galactosidase A deficiency, resulting in the accumulation of globotriaosylceramide (Gb-3) and its metabolite globotriaosylsphingosine (Lyso-Gb-3). Cardiovascular complications and hypertrophic cardiomyopathy (HCM) are the most frequent manifestations of FD. While an echocardiogram and cardiac MRI are clinical tools to assess cardiac involvement, hypertrophic pattern variations and fibrosis make it crucial to identify biomarkers to predict early cardiac outcomes. This study aims to investigate potential biomarkers associated with HCM in FD: transforming growth factor-β1 (TGF-β1), TGF-β active form (a-TGF-β), vascular endothelial growth factor (VEGF-A), and fibroblast growth factor (FGF2) in 45 patients with FD, categorized into cohorts based on the HCM severity. TGF-β1, a-TGF-β, FGF2, and VEGF-A were elevated in FD. While the association of TGF-β1 with HCM was not gender-related, VEGF was elevated in males with FD and HCM. Female patients with abnormal electrocardiograms but without overt HCM also have elevated TGF-β1. Lyso-Gb3 is correlated with TGF-β1, VEGF-A, and a-TGF-β1. Elevation of TGF-β1 provides evidence of the chronic inflammatory state as a cause of myocardial fibrosis in FD patients; thus, it is a potential marker of early cardiac fibrosis detected even prior to hypertrophy. TGF-β1 and VEGF biomarkers may be prognostic indicators of adverse cardiovascular events in FD.Keywords
Funding Information
- Sanofi (SGZ-2020-12892)
This publication has 56 references indexed in Scilit:
- Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsOrphanet Journal of Rare Diseases, 2013
- Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 MappingCirculation: Cardiovascular Imaging, 2013
- Transforming growth factor (TGF)-β signaling in cardiac remodelingJournal of Molecular and Cellular Cardiology, 2011
- Differences in Fabry Cardiomyopathy Between Female and Male PatientsJACC: Cardiovascular Imaging, 2011
- Association between transforming growth factor-β1 and left ventricular mass and diameter in hypertensive patientsJournal of the American Society of Hypertension, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Plasma Levels of Transforming Growth Factor-β1 Reflect Left Ventricular Remodeling in Aortic StenosisPLOS ONE, 2009
- Myofibroblast contraction activates latent TGF-β1 from the extracellular matrixJournal of Cell Biology, 2007
- Role of Angiogenesis in Cardiovascular DiseaseCirculation, 2005
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002